Methylphenidate (HCl)

Methylphenidate (HCl) is a centrally acting sympathomimetic agent. Methylphenidate (HCl) is a central nervous system stimulant. It increases mental alertness. Methylphenidate (HCl) is used in the treatment of narcolepsy. Methylphenidate (HCl) is used as an adjunct therapy to remedial measures (psychological, educational and social) in the management of minimal brain dysfunction.

Methylphenidate (HCl) is primarily indicated in conditions like Attention deficit hyperactivity disorders, Depression, Narcolepsy, and can also be given in adjunctive therapy as an alternative drug of choice in Apathetic behavior, Chronic fatigue, Drug-induced lethargy, Psychoneurosis, Stuttering.

Methylphenidate (HCl) is contraindicated in conditions like Agitation, Alcohol dependence, Anxiety, Cardiac arrhythmia, Epilepsy, Glaucoma, Hypertension, Psychosis, Thyrotoxicosis, Gille de la Tourette syndrome, Hypersensitivity, Tension.

The severe or irreversible adverse effects of Methylphenidate (HCl), which give rise to further complications include Depression, Agitation, Hyperactivity. Methylphenidate (HCl) produces potentially life-threatening effects which include Convulsions, Cardiac arrhythmias. which are responsible for the discontinuation of Methylphenidate (HCl) therapy. The signs and symptoms that are produced after the acute overdosage of Methylphenidate (HCl) include Vomiting, Tachycardia, Cardiac arrhythmias, Convulsions, Confusion, Hallucinations, Sweating, Hyperventilation, Tremor, Mydriasis, Delusions, Pallor, Elevation of BP, Hyperreflexia, Respiratory stimulation, Cardiac insufficiency, Loss of consciousness, Muscle twitching. The symptomatic adverse reactions produced by Methylphenidate (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Nausea, Anorexia, Restlessness, Palpitation, Tachycardia, Insomnia, Nervousness, Abdominal pain, Weight loss.

Perform periodic blood counts, platelets and differential counts during prolong therapy with methylphenidate. Abrupt discontinuation after long-term administration is not recommended. Methylphenidate should be used cautiously in the patient with the history of the emotional instability, alcoholism or the substance abuse because the potential for abuse is increased.

Drug should not be given to Paediatrics, Pregnant Mothers, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

5 to 20 mg (12 (12.5)) 8 hourly PO —

0.2 mg/kg (0.2 (0.2)) 12 hourly Oral — Dose for 5-12 Yrs of Children

No neonatal dosage information is recorded for this medicine yet.

Methylphenidate (HCl) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAdrenalineChlorpromazine (HCl)Clomipramine (HCl)Desipramine (HCl)Dothiepin (HCl)Doxepin (HCl)Imipramine (HCl)Imipramine (HCl)IsocarboxazidPhenylbutazone Phenytoin (Na)Phenytoin (Na)PrimidoneThiopentone (Na)Trimipramine (Maleate) These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Tab Store Below 40°C. Protect from Sunlight and Moisture.